Mobius Therapeutics was founded in 2006 on the principle of resolution of challenges in the ophthalmic pharmaceutical market. It’s flagship product, Mitosol, was approved by FDA in 2012 and has become the “gold standard” for preparation and delivery of mitomycin-c in the ophthalmic operating room.
But it does not end there. Ophthalmic perioperative injectables are a matter of daily frustration. They are often off-label, must be sourced in inconvenient compounded formulations, are presented in enormous, multi-dose vials, and have never been designed for use in the sterile environment of the ophthalmic OR.
Mobius’s expanded mission is founded on the recognition of these needs, and subsequently directing our efforts to the optimization of the products to the ophthalmic OR. Only then do we seek regulatory approval, offering providers and patients the security of FDA approved and cGMP compliant products, designed from the outset to meet the demanding needs of the ophthalmic OR.
Our current portfolio is only the beginning. With major products in various stages of design and regulatory submission, we look forward to a future of synergistic collaboration with the ophthalmic community.
WMT-022 Rev 01/2018